View Clinical Trial (Medical Research Study)

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis - NCT00217295-19146(Clinical Trial 130648)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Philadelphia
State:  
PA
Zip Code: 19146
Conditions: Multiple Sclerosis
Purpose: This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of brain shrinkage) and by clinical assessment scores to evaluate disease progression.
Study summary: The protocol requires all participants to be treated with Avonex and in addition patients will be blindly assigned to either a group who receive Topamax or a placebo control. Repeated neurological and clinical examinations are performed with laboratory tests to determine any possible adverse drug effects. The scaled neurologic examinations (EDSS and MSFC) and brain MRI's are done at regular intervals to evaluate possible treatment effects.
Criteria: Inclusion Criteria: Relapsing-remitting multiple sclerosis - Exclusion Criteria: Secondary progressive multiple sclerosis Contraindication to MRI Systemic disease Pregnancy -
Study is available at: Multiple Sclerosis Institute
Philadelphia, PA 19146
United States

Primary Contact:
Jeffrey I Greenstein, MD
Phone: 215-985-2245

Secondary Contact:
Jeffrey I Greenstein, MD
Phone: 215-985-2245
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 21, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.